Products

Analysis of more than 16,000 lumbar fusion procedures showed similar clinical outcomes with average hospital fees up to $50,000 lower using ViviGen.

TheraCell licensed the technology to AlloSource to market AlloFuse Cortical Fibers and AlloFuse Fiber Boats, and to produce private-label products.

MOTYS placental tissue particulate will be evaluated for safety and efficacy to treat osteoarthritis of the knee.

First patients completed 12-month follow-up in its prospective, multi-center study of ProChondrix CR to repair knee articular cartilage defects.

FIBRI-CELL with Osteo-Spin technology offers a novel approach to enhance traditional bone graft substitutes for orthopedic fusion procedures.

CVS Caremark manages the drug benefits for more than 40 million lives, which includes the prescription drug benefits of 6 million Aetna members.

i-FACTOR+ Matrix is now fully available in Canada through distributor Surgi-One, and can be used in both spine and general orthopedic applications.

TheraCell completed the first three surgical cases with the TheraFuze DBF Fiber Anchor, offering surgeons improved screw fixation and bone conservation.

The new Avitus Bone Harvester 6mm Edition features a 30% smaller pilot hole entry than the standard edition.

90% of patients show bone fusion as well as strong clinical improvements in function and pain at 24 months follow-up with a good product safety profile.